Miragen Therapeutics, Inc. (MGEN) financial statements (2021 and earlier)

Company profile

Business Address 6200 LOOKOUT ROAD
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:2762473115
Cash and cash equivalents 33473115
Short-term investments230    
Other undisclosed cash, cash equivalents, and short-term investments25     
Restricted cash and investments     0
Receivables001101
Inventory, net of allowances, customer advances and progress billings   000
Inventory   000
Deferred costs  0   
Assets held-for-sale, not part of disposal group   0 
Other undisclosed current assets333000
Total current assets:3065524127
Noncurrent Assets
Property, plant and equipment111 11
Deferred costs     0
Other noncurrent assets 00   
Other undisclosed noncurrent assets    00
Total noncurrent assets:111 11
TOTAL ASSETS:3066524138
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities644411
Accounts payable111000
Accrued liabilities543310
Employee-related liabilities     0
Debt42   0
Due to related parties   111
Other liabilities   00 
Other undisclosed current liabilities     (0)
Total current liabilities:1074522
Noncurrent Liabilities
Long-term debt and lease obligation4810   
Long-term debt, excluding current maturities4810   
Liabilities, other than long-term debt 00 00
Other liabilities 00 00
Total noncurrent liabilities:4810 00
Total liabilities:151514522
Stockholders' equity
Stockholders' equity attributable to parent165139(0)106
Common stock000000
Additional paid in capital184177132302813
Accumulated other comprehensive loss (0)    
Accumulated deficit(168)(126)(94)(31)(18)(7)
Total stockholders' equity:165139(0)106
TOTAL LIABILITIES AND EQUITY:3066524138

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues484366
Revenue, net4334
Cost of revenue   (3)(2)(3)
Gross profit:484133
Operating expenses(46)(41)(31)(13)(14)(11)
Other undisclosed operating income (loss)    (1)1
Operating loss:(42)(33)(27)(13)(11)(7)
Nonoperating income (expense)110  (0)
Loss on contract termination     (0)
Interest and debt expense(1)(1)(0)(0)(0)(1)
Net loss:(42)(33)(27)(13)(11)(8)
Other undisclosed net income attributable to parent     0
Net loss attributable to parent:(42)(33)(27)(13)(11)(8)
Preferred stock dividends and other adjustments  (0)   
Net loss available to common stockholders, diluted:(42)(33)(27)(13)(11)(8)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(42)(33)(27)(13)(11)(8)
Comprehensive loss:(42)(33)(27)(13)(11)(8)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)    
Comprehensive loss, net of tax, attributable to parent:(42)(33)(27)(13)(11)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: